Sec Form 4 Filing - MILLER TYRONE @ 60 DEGREES PHARMACEUTICALS, INC. - 2023-11-21

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person MILLER TYRONE 2. Issuer Name and Ticker or Trading Symbol 60 DEGREES PHARMACEUTICALS, INC. [ SXTP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO (Last) (First) (Middle) C/O 60 DEGREES PHARMACEUTICALS, INC., 1025 CONNECTICUT AVENUE NW SUITE 1000 3. Date of Earliest Transaction (MM/DD/YY) 11/21/2023 (Street) WASHINGTON, DC20036 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock ( 1 ) 04/12/2024 A 60,000 ( 1 ) A $ 0.2668 161,928 ( 1 ) D Common Stock ( 2 ) 05/16/2024 A 15,000 ( 2 ) A $ 0.223 176,928 ( 2 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 3 ) $ 0 11/21/2023 A 75,000 ( 3 ) ( 3 ) ( 3 ) Common Stock 75,000 ( 3 ) $ 0 75,000 D Restricted Stock Units ( 3 ) ( 4 ) $ 0 04/12/2024 M 60,000 ( 4 ) ( 4 ) ( 4 ) Common Stock 60,000 ( 4 ) $ 0 15,000 D Restricted Stock Units ( 3 ) ( 5 ) $ 0 05/16/2024 M 15,000 ( 5 ) ( 5 ) ( 5 ) Common Stock 15,000 ( 5 ) $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other MILLER TYRONE C/O 60 DEGREES PHARMACEUTICALS, INC. 1025 CONNECTICUT AVENUE NW SUITE 1000 WASHINGTON, DC20036 CFO Signatures /s/ Tyrone Miller 05/21/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Tyrone Miller was granted a total of 75,000 restricted stock units ("RSUs") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the "4/24 Shares"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock. ( 2 )15,000 shares underlying the RSUs were settled on May 16, 2024 (the "5/24 Shares"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock. ( 3 )Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. ( 4 )60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. ( 5 )15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.